Oragenics Competitors

Oragenics (NYSEAMERICAN:OGEN) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 44.8% of Evofem Biosciences shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Comparatively, 9.9% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and Evofem Biosciences, as provided by MarketBeat.

Evofem Biosciences has a consensus target price of $9.7143, indicating a potential upside of 152.32%. Given Evofem Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Evofem Biosciences is more favorable than Oragenics.

Profitability

This table compares Oragenics and Evofem Biosciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Oragenics and Evofem Biosciences' gross revenue, earnings per share and valuation.

Evofem Biosciences is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

Evofem Biosciences beats Oragenics on 7 of the 10 factors compared between the two stocks.

Oragenics (NYSEAMERICAN:OGEN) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, NextCure has a beta of -0.4, indicating that its stock price is 140% less volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 66.3% of NextCure shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Comparatively, 9.1% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and NextCure, as provided by MarketBeat.

NextCure has a consensus target price of $23.3333, indicating a potential upside of 104.50%. Given NextCure's stronger consensus rating and higher possible upside, analysts plainly believe NextCure is more favorable than Oragenics.

Profitability

This table compares Oragenics and NextCure's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Oragenics and NextCure's gross revenue, earnings per share and valuation.

Oragenics has higher earnings, but lower revenue than NextCure. NextCure is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

NextCure beats Oragenics on 7 of the 12 factors compared between the two stocks.

Oragenics (NYSEAMERICAN:OGEN) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Theratechnologies has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 6.3% of Theratechnologies shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and Theratechnologies, as provided by MarketBeat.

Theratechnologies has a consensus target price of $7.1250, indicating a potential upside of 101.84%. Given Theratechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Theratechnologies is more favorable than Oragenics.

Profitability

This table compares Oragenics and Theratechnologies' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Oragenics and Theratechnologies' gross revenue, earnings per share and valuation.

Theratechnologies has higher revenue and earnings than Oragenics. Theratechnologies is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

Theratechnologies beats Oragenics on 9 of the 13 factors compared between the two stocks.

Oragenics (NYSEAMERICAN:OGEN) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 38.4% of BELLUS Health shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Comparatively, 24.2% of BELLUS Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and BELLUS Health, as provided by MarketBeat.

BELLUS Health has a consensus target price of $8.6167, indicating a potential upside of 114.34%. Given BELLUS Health's stronger consensus rating and higher possible upside, analysts plainly believe BELLUS Health is more favorable than Oragenics.

Profitability

This table compares Oragenics and BELLUS Health's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Oragenics and BELLUS Health's gross revenue, earnings per share and valuation.

Oragenics has higher earnings, but lower revenue than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Summary

BELLUS Health beats Oragenics on 8 of the 13 factors compared between the two stocks.

Oragenics (NYSEAMERICAN:OGEN) and Guardion Health Sciences (NASDAQ:GHSI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Profitability

This table compares Oragenics and Guardion Health Sciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Oragenics and Guardion Health Sciences' gross revenue, earnings per share and valuation.

Guardion Health Sciences has higher revenue and earnings than Oragenics.

Analyst Recommendations

This is a breakdown of recent ratings for Oragenics and Guardion Health Sciences, as provided by MarketBeat.

Insider & Institutional Ownership

12.8% of Oragenics shares are owned by institutional investors. Comparatively, 5.3% of Guardion Health Sciences shares are owned by institutional investors. 9.9% of Oragenics shares are owned by company insiders. Comparatively, 3.9% of Guardion Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Oragenics has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Guardion Health Sciences has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Guardion Health Sciences beats Oragenics on 5 of the 8 factors compared between the two stocks.

Alpine Immune Sciences (NASDAQ:ALPN) and Oragenics (NYSEAMERICAN:OGEN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Profitability

This table compares Alpine Immune Sciences and Oragenics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Alpine Immune Sciences and Oragenics' gross revenue, earnings per share (EPS) and valuation.

Oragenics has lower revenue, but higher earnings than Alpine Immune Sciences. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alpine Immune Sciences and Oragenics, as provided by MarketBeat.com.

Alpine Immune Sciences presently has a consensus target price of $19.40, indicating a potential upside of 49.81%. Given Alpine Immune Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alpine Immune Sciences is more favorable than Oragenics.

Insider and Institutional Ownership

52.9% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 12.8% of Oragenics shares are owned by institutional investors. 76.1% of Alpine Immune Sciences shares are owned by company insiders. Comparatively, 9.9% of Oragenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Alpine Immune Sciences has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Summary

Alpine Immune Sciences beats Oragenics on 9 of the 13 factors compared between the two stocks.